[{"id":"05a3d63a-1145-4861-9039-4df131c43c8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05562024","created_at":"2022-09-30T19:56:03.957Z","updated_at":"2024-07-02T16:35:54.680Z","phase":"Phase 1","brief_title":"TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma","source_id_and_acronym":"NCT05562024","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAA6-CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/18/2025","primary_completion_date":" 12/18/2025","study_txt":" Completion: 02/18/2039","study_completion_date":" 02/18/2039","last_update_posted":"2023-02-27"},{"id":"cdbcdeec-fdcc-4b9f-a012-585b387709ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05190185","created_at":"2022-01-13T14:57:06.433Z","updated_at":"2024-07-02T16:36:18.514Z","phase":"Phase 1","brief_title":"A Clinical Trial of TAA06 Injection in Advanced Solid Tumors","source_id_and_acronym":"NCT05190185","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAA6-CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-01-13"},{"id":"6723422f-b2f2-4eaf-9e70-791a4494fab0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04864821","created_at":"2021-04-29T12:55:41.176Z","updated_at":"2024-07-02T16:36:30.616Z","phase":"Phase 1","brief_title":"Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor","source_id_and_acronym":"NCT04864821","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAA6-CAR-T"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/14/2021","start_date":" 05/14/2021","primary_txt":" Primary completion: 05/14/2022","primary_completion_date":" 05/14/2022","study_txt":" Completion: 05/14/2023","study_completion_date":" 05/14/2023","last_update_posted":"2021-05-06"}]